Search

everythinglearnresearchcommunity

for

Search:↓

Low SHBG and high FAI, FT, and DHEAS levels are effective in identifying PCOS.

Combination therapy with steroids and pimecrolimus improved or stabilized hair loss in most patients with Frontal Fibrosing Alopecia, who also had a high rate of hypothyroidism.

Finasteride and dutasteride increase sexual dysfunction reports.

Finasteride can cause a unique skin reaction on the penile shaft.

Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.

Porcine PRP can replace FBS and promote hair growth.

Platelet-rich plasma therapy may help treat folliculitis decalvans but benefits might not last without ongoing treatment.

New methods efficiently isolate dermal papilla cells from hair follicles, preserving their characteristics better than traditional methods.

Diphencyprone treatment protocols could be simplified as no harm occurred despite not fully following them.

A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.

PCOS causes sexual dysfunction, needing comprehensive treatment.

Lower finasteride doses had more side effects; dutasteride caused back pain; more research needed on post-finasteride syndrome.

Fibrosing alopecia can be diagnosed without typical signs of lichen planopilaris.

Paeoniflorin protects brain cells by involving a specific protein and neurosteroids.

Children with Parry Romberg Syndrome had successful facial fat-grafting surgeries after disease stabilization with no complications.

Flibanserin's effectiveness for low sexual desire in premenopausal women may vary based on hormone levels, with normal hormone levels showing better responses.

PDGF signaling is crucial for cell development, wound healing, and fluid regulation in the body.

Fibroblast changes in systemic sclerosis may help understand disease severity and treatment.

Finasteride may cause changes in dopamine-related genes, possibly leading to post-finasteride syndrome.

Women with PCOS are more than twice as likely to develop nonalcoholic fatty liver disease.

The Fatty Liver Index (FLI) may not be enough to rule out non-alcoholic fatty liver disease in lean women with polycystic ovary syndrome.

Current treatments for postmenopausal frontal fibrosing alopecia stop hair loss but don't regrow hair.

The conclusion is that more research is needed to understand if the drug finasteride causes Post-Finasteride Syndrome or if it's due to individual genetic makeup.

Post-finasteride syndrome's existence is uncertain; more research needed.

Some people experience lasting sexual, psychological, and sleep problems after using finasteride or SSRI antidepressants, possibly due to similar underlying causes.

New method measures female hair loss: Female Pattern Hair Loss Severity Index (FPHL-SI).